Montai is aggregating and curating the world's largest, fully-annotated collection of Anthromolecules — bioactive compounds humans have chronically consumed. This richly diverse chemical space offers molecular scaffolds that differ by more than 99% from those found in traditional drug-development libraries such as Enamine or DNA-encoded libraries. Embedded within this chemically diverse space are numerous validated mechanisms of action — such as covalent binders, allosteric inhibitors, molecular glues, macrocycles, and protein-protein interaction inhibitors — that are well suited for addressing complex biology.

Montai has developed proprietary AI and ML tools to generate and curate more than 1 billion synthetically accessible, drug-like analogs derived from Anthromolecules. We continue to expand our chemical space to open access for the first time to the broadest diversity of nature-encoded chemistry for modern drug discovery.

CONECTA AI is powered by advanced multimodal foundation models trained on over a billion curated and proprietary data points, and 100 biological pathways across five therapeutic areas. This foundation enables efficient and systematic mapping of diverse chemical space to established biological drivers of chronic disease, and expands the landscape of tractable, orally available therapeutics.

CONECTA's proprietary AI system overcomes prior challenges such as polypharmacy and accessibility in exploiting diverse chemistry through target specific bioactivity modeling and mechanism-directed compound prioritization. CONECTA's multimodal in silico ranking system integrates predictions of bioactivity with more than 60 physiochemical and drug-like parameters (e.g., solubility, permeability, toxicity, manufacturability) to precisely identify the top on-mechanism candidates. This pathway-selective ranking across rich chemical diversity delivers the equivalent of 1,000+ years of experimental screening in under two days.

By enabling predictive, high-resolution prioritization at unprecedented scale, CONECTA empowers researchers and drug developers to uncover the most promising starting points for interrogating and modulating complex biology.

CONECTA enables unprecedented integrated decisioning across expert domains including — biologists, chemists, toxicologists, manufacturing, translational medicine, and drug developers. The integrated team defines a precise target candidate profile (TCP) and then collaborates with CONECTA's AI/ML experts to uncover the hidden potential in diverse chemistry. This approach allows efficient discovery and advancement of multiple uncorrelated hits, leads, and development candidates (DCs).

CONECTA's approach provides several key advantages:

• Unparalleled access to diverse chemotypes and mechanisms
• Highly efficient wet lab — focused on most promising chemistry, AI medchem assist
• Higher probability of success and clinical optionality — multiple DCs and optimal translational profiles for different indications